Panelists discuss how biosimilars for adalimumab have faced unique challenges in the prescription benefit space compared with earlier oncology biosimilars, highlighting the importance of interchangeability designation, advance planning, and stakeholder education when implementing biosimilar adoption strategies.
Evolution of the Biosimilar Landscape
Key Themes:
Key Points for Physicians:
Notable Insights:
Experience implementing oncology biosimilars has created pathways for other biosimilars, though with important differences between medical and pharmacy benefit medications.
Clinical Significance: Adalimumab biosimilars represent a critical opportunity to reduce one of health care’s highest drug expenditures while maintaining clinical efficacy. However, they require strategic implementation approaches that differ from previous biosimilar experiences.
Ovarian Cancer Survival Gaps Persist Across Racial, Ethnic Groups
May 27th 2025Abstracts published ahead of the 2025 American Society of Clinical Oncology Annual Meeting found persistent ovarian cancer survival disparities among racial and ethnic subgroups, particularly within disaggregated Asian American, Native Hawaiian, and Pacific Islander populations.
Read More